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Key questions
What is already known?
 ► Prior reviews reported a small body of good-quality 
cost-effectiveness analysis (CEA) studies relating to 
China.
 ► They identified relatively few studies compared with 
our extractions from the Tufts Medical Center Cost-
Effectiveness Analysis Registry and Global Health 
Cost-Effectiveness Analysis Registry and they were 
limited in their comparisons with the international 
CEA literature.
What are the new findings?
 ► This review found an expanding body of well-con-
structed cost-per-quality-adjusted life-year and 
cost-per-disability-adjusted life-year studies relating 
to mainland China.
 ► There were some unique features of the CEA litera-
ture for China compared with the international CEA 
literature such as a different sponsorship pattern, 
with the government funding a higher proportion of 
studies.
What do the new findings imply?
 ► The profile of CEA is growing in China although the 
number of published studies remains a small pro-
portion of studies published globally.
AbsTrACT
Introduction Cost-effectiveness analysis (CEA) is playing 
an increasingly important role in informing healthcare 
decision-making in China. This study aims to review 
the published literature on CEA in mainland China and 
describe its characteristics and evolution. We provide 
recommendations on the future direction of CEA as a 
methodology and as a tool to support healthcare decision-
making in China.
Methods English-language cost-per-quality-adjusted 
life-year (QALY) and cost-per-disability-adjusted life-year 
(DALY) publications relating to mainland China were 
reviewed using the Tufts Medical Center Cost-Effectiveness 
Analysis Registry and Global Health Cost-Effectiveness 
Analysis Registry through 2017. Study features were 
summarised using descriptive statistics. Changes in study 
methodology over time were analysed by trend test, and 
study characteristics influencing the incremental cost-
effectiveness ratio (ICER) of cost-per-QALY studies were 
investigated using logistic regression.
results 170 studies were identified reporting CEA for 
mainland China (cost/QALY=125, cost/DALY=45) since 
1998. The number and quality of studies has increased 
over the past two decades, with significantly more cost-
per-QALY studies compared with cost-per-DALY studies 
(p<0.0001) and more studies with authors affiliated with 
Chinese institutions (p=0.0002). The average quality 
score was 5.04 out of 7 for cost-per-QALY and 4.70 for 
cost-per-DALY studies based on Registry reviewers’ 
subjective assessment of overall quality (methods, 
assumptions and reporting practices). The median ICER 
reported for interventions for oncology patients was higher 
(US$26 694 per QALY) than the median ICER reported 
for all interventions (US$11 503 per QALY). Oncology 
interventions were associated with the likelihood of 
reporting higher ICERs than the median ICER (p=0.003).
Conclusion The number of English-language published 
CEA studies relating to China has grown rapidly over 
the past 20 years. In terms of quality, the China studies 
compare favourably with international studies, although 
they remain a small proportion of studies globally.
InTroduCTIon
Cost-effectiveness analysis (CEA) quantifies 
the incremental costs and benefits of inter-
ventions compared with alternative uses of 
resources, supporting judgements on whether 
health technologies provide good value.1 
Faced with competing demands for limited 
healthcare budgets, CEA is increasingly used 
to inform healthcare decision-making around 
the world. Examples of national health tech-
nology assessment (HTA) agencies include 
the National Institute for Health and Care 
Excellence in the UK, the Canadian Agency 
for Drugs and Technologies in Health in 
Canada and the Agency for Care Effectiveness 
in Singapore.2–4
Several studies have reviewed the interna-
tional CEA literature, finding a rapid growth 
in studies and the expansion of the method-
ology to non-Western countries.5 6 In China, 
there is a desire to move towards a data-driven 
healthcare system with China’s national 
health strategy7 ‘Healthy China 2030’ setting 
specific indicators to measure success7; in 
addition, a number of health policy reforms 
have promoted HTA and comparative effec-
tiveness research in recent years.8 Guidelines 
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for conducting pharmacoeconomic evaluations in China 
were first published in 2011 and are updated as methods 
develop.9
However, previous reviews have identified relatively 
small numbers of published CEA studies relating to China. 
A systematic review of pharmacoeconomic studies in the 
Asia-Pacific region included 128 studies, but none of the 
included studies were conducted in China.10 Another 
systematic review of pharmacoeconomic publications 
produced in China between 2006 and 2012 included 20 
studies.11 While another systematic review of the quality 
of pharmacoeconomic publications from China through 
2014 included 32 studies.12
Two special cases of CEA, which differ in their quan-
tification of health benefit, have become increasingly 
prominent in recent decades. The first uses the qual-
ity-adjusted life-year (QALY) as a measure of health 
benefit. The QALY weights each year of life lived using 
a preference for health state (utility) anchored so that 1 
represents perfect health and 0 is equivalent to the state 
of being dead.13 Many national HTA agencies recom-
mend the number of QALYs gained as a unit of benefit 
for evaluations.3
The second case uses the disability-adjusted life-year 
(DALY) as a measure of health benefit. The DALY 
weights years of life using equivalent years of ‘healthy’ life 
lost by virtue of being in states of poor health or disability. 
The DALY is frequently used when assessing the impact 
of public health interventions with benefit in this case 
expressed in terms of DALYs averted. The WHO uses the 
metric in its Global Burden of Disease Study.14
This study aims to review the published literature on 
CEA (cost per QALY gained and cost per DALY averted) 
of health technologies in mainland China to describe its 
characteristics and evolution in order to make recom-
mendations on future directions for researchers and 
policymakers.
MeTHods
Cost-effectiveness Analysis registry
The Tufts Medical Center Cost-Effectiveness Analysis 
Registry (CEA Registry) is a curated database with detailed 
information on over 7200 cost-per-QALY gained studies 
and 18 000 incremental cost-effectiveness ratios (ICER) 
published in the English-language peer-reviewed litera-
ture since 1976. While search strategy and methodology 
for the Registry have been described previously6 and 
made available in the online supplementary appendix, 
here we provide a summary. The CEA Registry only 
contains information from the original studies reporting 
ICERs (ie, excluding review, editorial or methodolog-
ical articles). Followed by literature search, at least two 
reviewers independently conduct a series of screening. 
After a consensus meeting to determine whether each 
study is suitable for full or partial or no data collection, 
data are extracted from each accepted study and made 
available on the CEA Registry, including the following 
key variables: country, disease, intervention description, 
intervention type and comparator description.
The Global Health CEA Cost-Effectiveness Analysis 
Registry (GH CEA Registry; www. ghcearegistry. org) 
follows a similar methodology to the CEA Registry to 
identify cost-per-DALY studies. The GH CEA Registry 
has over 600 articles containing cost-per-DALY averted 
estimates and over 5000 ratios published in the peer-re-
viewed literature since 1995. For this study, articles that 
included mainland China (excluding Hong Kong, Macau 
and Taiwan) as a primary or secondary geographic region 
were extracted from both the CEA Registry and GH CEA 
Registry on 17 May 2018.
Patient and public involvement
Patients were not involved in this research.
Variables
Data are collected for each article on 40 variables, 
including author affiliation, study country, study spon-
sorship, a description of each ratio’s intervention, 
comparator, target population, the methodology used 
to measure costs and health utilities, and methods used 
to calculate cost-utility ratios. All sources of sponsorship 
and all author affiliations are recorded, meaning that a 
single study may have several sponsorships or author affil-
iations. The quality score available from the CEA/GH 
CEA Registry is assigned by two highly trained Registry 
reviewers after a consensus meeting. The score is assigned 
on an interval scale from 1 (low) to 7 (high) based on the 
following criteria:
 ► Methods and results were communicated clearly and 
transparently to enable easy interpretation.
 ► Time horizon was of sufficient length and discount 
rate appropriate.
 ► Detailed disaggregated cost and QALY information 
was provided and recalculated ICER was correct (or 
did not differ by more than 10%).
 ► Comprehensive characterisation of uncertainty 
(sensitivity analyses).
 ► Explicit reporting of utility weights (includes utility 
weight value and estimation method).
 ► Subgroup analysis performed.
 ► Non-health effects and/or spillover effects were 
quantified.
In addition to the standard variables contained within 
the registry, for included studies we extracted two addi-
tional variables: (1) the country of first author affiliation 
and (2) the cost-effectiveness threshold used to deter-
mine if the intervention was likely to be cost-effective.
Analysis
Descriptive statistics were used to summarise key features 
of cost-per-QALY and cost-per-DALY studies in China. We 
further categorised studies featuring China, as having 
either a primary or secondary geographic focus. The 
geographic focus refers to the country to which the study’s 
results are applied. For example, if the primary country is 
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Table 1 Study characteristics
Variable QALY DALY
All
Primary 
geography=China All
Primary 
geography=China
Studies, n 125 121 45 23
Top three disease areas, 
name (%)
1 Oncology (34.7) Oncology (35.7) Infectious and parasitic 
diseases (62.2)
Infectious and 
parasitic diseases 
(60.9)
2 Infectious and 
parasitic diseases 
(25.7)
Infectious and 
parasitic diseases 
(25.5)
Endocrine, nutritional and 
metabolic diseases (11.1)
Endocrine, nutritional 
and metabolic 
diseases (13.0)
3 Endocrine, nutritional 
and metabolic 
diseases (14.9)
Endocrine, nutritional 
and metabolic 
diseases (15.3)
Oncology (6.7) Oncology (8.7)
First author affiliation=China, 
%
80.8 82.6 35.6 65.2
Academic author, % 79.2 79.3 82.2 58.3
Government sponsorship, % 42.4 42.1 51.1 41.7
Healthcare payer 
perspective, %
57.1 58.4 35.6 26.1
Quality score, mean 5.04 5.05 4.70 4.41
Disease area categories are based on International Classification of Diseases 10th Revision (ICD-10) chapters.
DALY, disability-adjusted life-year; QALY, quality-adjusted life-year.
defined as China, then the ICER represents the expected 
costs and QALYs if interventions were adopted in China. 
If the primary country is defined as another country, 
but the study includes a subanalysis for China, then the 
study is defined as having a secondary geographic focus 
of China. This differentiation is particularly relevant for 
cost-per-DALY studies that often cover multiple low and 
middle-income countries in a single evaluation. Studies 
were grouped by year of publication to describe study 
characteristics at different time points.
The Cochran-Armitage trend test was used to inves-
tigate trends over time. The association between study 
characteristics (study sponsors and first author affiliation 
and the time of publication) was tested.
ICER analysis focused on cost-per-QALY studies with 
a primary geographic region of China. Cost-per-DALY 
studies were excluded because the different benefit 
measures cause non-comparability issues, and the sample 
of cost-per-DALY studies with a primary geography of 
China was relatively small for meaningful investigation of 
their characteristics.
We conducted a statistical analysis to examine the 
association between study characteristics and the prob-
ability of being reported ICER is greater (or lower) than 
the overall median ICER. Analysis was limited to those 
ICERs that fell in the north-east quadrant (interven-
tion more costly and more effective than comparator). 
Using a logistic regression, the dependent variable was 
a dichotomous variable on whether the reported ICER 
(in 2017 US$) was higher than the median ICER. Inde-
pendent variables included disease area (oncology vs 
not oncology), study sponsor (industry vs non-industry), 
author affiliation (industry vs non- industry) and study 
quality (1–7 interval scale).
Each study may report one or more ICERs, which were 
defined by three characteristics: (1) the target popula-
tion, (2) the intervention, and (3) the comparator. This 
means no two ratios reported for the same paper should 
have identical entries for all three of these characteristics. 
If two values are reported for the same ratio (ie, the same 
three elements), the two ratios differ because of an alter-
native assumption (eg, the use of a societal perspective 
rather than a healthcare system perspective). Each ratio 
was assigned a weight of 1/n, where n was the number 
of ratios reported in an article to ensure that no single 
article disproportionately affected the results.
Statistical analysis was performed in Stata V.14 
(StataCorp).
resulTs
One hundred and seventy CEA studies with a geographic 
focus on mainland China were identified (QALY=125, 
DALY=45). Table 1 describes that the main study charac-
teristics and study references may be found in the online 
supplementary appendix. There was a marked difference 
in the scope of studies: 121 out of 125 (97%) cost-per-
QALY studies had a primary focus on China and the 
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Figure 1 Cost-effectiveness analysis (CEA) studies by year of publication. DALY, disability-adjusted life-year; QALY, quality-
adjusted life-year.
Table 2 Changes over time in study characteristics
1998–2010 
(n=26)
2011–2013 
(n=31)
2014–2015 
(n=43)
2016–2017 
(n=71)
Test for trend, 
P value
QALY as unit of health benefit, % 42.3 64.5 81.4 83.1 <0.0001
First author at Chinese institution, % 38.5 73.3 67.4 78.9 0.0002
Quality score (cost-per-QALY studies), mean 4.59 4.95 4.95 5.27 –
Quality score (cost-per-DALY studies), mean 4.43 4.60 4.81 5.04 –
DALY, disability-adjusted life-year; QALY, quality-adjusted life-year.
remaining four studies included China as a secondary 
focus. Only 23 out of 45 (51%) cost-per-DALY studies had 
a primary focus on China and the remaining 22 studies 
included China as a secondary focus.
Figure 1 shows that the number of studies published 
has grown over the past 20 years. The first cost-per-DALY 
study was published in 1998 and the first cost-per-QALY 
studies 10 years later in 2008. Since 2008, cost-per-QALY 
studies have dominated the China CEA literature and 
have accounted for 50% or more of the CEA studies 
published and reached a high of 94% of CEA studies 
in 2016. Table 2 shows the proportion of studies with 
certain characteristics over time. The table shows that the 
proportion of studies using QALY as the unit of health 
benefit, the proportion of studies with first author affili-
ated with an institution in China and the mean subjective 
quality score all increase over time. The Cochran-Ar-
mitage trend test was significant for the proportion of 
studies using QALYs (p<0.0001) and the proportion of 
studies with first author affiliated with an institution in 
China (p=0.0002).
disease area
Disease areas were classified by the 21 International Clas-
sification of Diseases 10th Revision chapters. The top 
three disease areas covered by cost-per-QALY studies 
were oncology (35%), infectious and parasitic diseases 
(26%) and endocrine, metabolic and nutritional diseases 
(15%). Other disease areas accounted for 25% of cost-
per-QALY studies in the Registry, and less than 10% indi-
vidually.
The top three disease areas covered by cost-per-DALY 
studies were the same as for cost-per-QALY studies, 
although in different orders and proportions. They were 
infectious and parasitic diseases (62%), endocrine, meta-
bolic and nutritional diseases (11%) and oncology (7%). 
Other disease areas accounted for 20% of cost-per-DALY 
studies in the Registry, and less than 5% individually.
Authorship
The location of authors varied between the cost-per-
QALY and cost-per-DALY studies. For QALY studies, 
101 (81%) of first authors were affiliated with institu-
tions in mainland China. In contrast, 16 (36%) of DALY 
studies had a first author affiliation in mainland China. 
The difference may be explained by the different scope 
of QALY and DALY studies: when only studies with a 
primary focus on China were included, 100/101 (99%) 
of QALY studies and 15/16 (94%) of DALY studies were 
authored in China.
Figure 2 shows the affiliations of all authors of cost-per-
QALY and cost-per-DALY studies. Most cost-per-QALY 
and cost-per-DALY studies included authors affiliated with 
academic institutions (99, 55%), followed by healthcare 
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Figure 2 Characteristics of cost-effectiveness analysis (CEA) studies. (A) Author affiliations. (B) Source of sponsorship. 
*Includes academic. **Includes intergovernmental organisations. DALY, disability-adjusted life-year; QALY, quality-adjusted life-
year.
institutions (45, 25%). Authors with government, 
industry and consultancy affiliations each accounted for 
less than 10% of studies.
study sponsorship
As depicted in figure 2, academia and government were 
sponsors of approximately half of cost-per-QALY and 
cost-per-DALY studies. Industry sponsored 17 (16%) of 
the cost-per-QALY studies. Of these studies, no single 
company was a dominant sponsor, with top sponsors 
AstraZeneca, Sanofi and Novo Nordisk each accounting 
for three studies. Only 2 (4%) of cost-per-DALY studies 
were sponsored by industry, while foundations and inter-
governmental organisations sponsored 19 (41%) studies.
Quality
The mean subjective quality score was 5.04 (SD 1.17) out 
of 7 for cost-per-QALY studies. This compares favourably 
with international studies, which averaged a score of 4.20 
in a previous report from the same database, although it 
should be noted that the general quality of CEA studies 
may have improved between our analysis and this earlier 
publication, and that the quality score is a relatively crude 
measure.5 The mean subjective quality score was 4.70 
(SD 0.97) for cost-per-DALY studies, which was slightly 
lower than the average of 4.89 reported for a previous 
study using the GH CEA Registry.15 Online supplemen-
tary appendix table A1 reports additional key criteria of 
the quality of cost-per-QALY and cost-per-DALY studies. 
These criteria were consistent with those that have been 
reported in previous publications using the CEA Registry 
to aid comparison. Overall, cost-per-DALY studies scored 
lower quality than cost-per-QALY studies, but the differ-
ence is particularly notable when examining the propor-
tion of studies conducting incremental CEA correctly. 
While 80.0% of cost-per-QALY studies conducted the 
incremental CEA correctly, this proportion was only 
57.8% for cost-per-DALY studies.
Incremental cost-effectiveness ratio
There were 296 ICERs for 121 cost-per-QALY studies 
with a primary geographic region of China. Of these 
296 ICERs, 208 (70%) were in the north-east quadrant, 
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Table 3 Logistic regression to identify factors that influence the probability that the ICER is greater than the weighted median 
for ratios in the north-east quadrant for cost-per-QALY studies
Model 1: disease area Model 2: full
Variable OR SE P value OR SE P value
Disease area=oncology 3.03*** 1.12 0.003 3.22*** 1.27 0.003
Sponsor=industry – – – 0.66 0.38 0.466
Author=industry – – – 0.43 0.39 0.352
Study quality (subjective score) – – – 1.27* 0.17 0.069
Constant 0.70* 0.15 0.086 0.21** 0.15 0.026
Observations 208  208  
Variables were coded as follows: disease area oncology=1, disease area not oncology=0; study sponsor included industry=1, sponsor did 
not include industry=0; author list included industry=1, author list did not include industry=0; study quality=1–7 interval scale (half-points 
were possible).
***p<0.01; **p<0.05; *p<0.10.
ICER, incremental cost-effectiveness ratio; OR, odds ratio; QALY, quality-adjusted life-year; SE, standard error.
meaning that interventions were more effective but 
more costly than the comparator, with a mean ICER of 
US$77 138 per QALY (SD: US$243 162) and a median 
of US$11 503. There were 52 ICERs for oncology inter-
ventions in the north-east quadrant and these had a 
mean ICER of US$118 505 per QALY (SD: US$228 438) 
and a median of US$26 694. Online supplementary 
appendix figure A1 shows these ICERs on a cost-effec-
tiveness plane. A further 33 ICERs fell into the north-
west quadrant (less effective, more costly/dominated), 
8 in the southwest quadrant (less effective, less costly) 
and 47 in the southeast quadrant (more effective, less 
costly/dominant).
Table 3 reports the results of logistic regression of the 
ICERs of cost-per-QALY studies in the north-east quad-
rant of the cost-effectiveness plane. Model 1 shows that 
ICERs for oncology, the most common disease area, 
were likely to be higher than ICERs for other disease 
areas (OR 3.03, 95% CI 1.47 to 6.27). After including 
the additional variables for study quality, pharmaceu-
tical industry authorship and pharmaceutical industry 
sponsorship, model 2 shows that, controlling for quality 
(subjective quality score), ratios for oncology studies 
remained likely to be higher (OR 3.22, 95% CI 1.49 to 
6.98). Neither authorship nor sponsorship by industry 
was associated with the chance of an ICER being higher 
than the median.
Studies applied a variety of cost-effectiveness thresholds 
to determine if the intervention was likely to be cost-ef-
fective. The most commonly used threshold was three 
times country-level gross domestic product (GDP) per 
capita used in 59 (49%) of the 121 cost-per-QALY studies 
with a primary geographic focus on China. GDP-based 
thresholds including one time, two times and ranges 
of 0–3 times GDP per capita were applied in 30 studies 
(25%) and a further 4 studies (3%) used other thresh-
olds. Eleven studies (9%) used a regional or city GDP per 
capita as the threshold. Seventeen studies (14%) failed to 
report a threshold.
dIsCussIon
This study identified the largest body of CEAs relating 
to China to date and compared it with the international 
CEA literature. The number of publications remains 
low by global standards, with just 170 studies identified. 
Proportionally, Chinese cost-per-QALY studies repre-
sent only 1.7% of the CEA Registry, reflecting the fact 
that historically the QALY has been the most commonly 
applied to high income settings.15 Chinese cost-per-DALY 
studies represent a larger share of 7.7% of the GH CEA 
Registry.
We hypothesise several reasons for the relatively low 
number of published CEA studies relating to China. 
First, some articles may be published in Chinese-lan-
guage journals, which are not recorded in the CEA 
Registry nor international indexing services such as 
PubMed. Second, government institutions conducting 
CEA studies may not choose to publish their analysis 
due to a political environment where decision-making 
process remains largely confidential with limited trans-
parency. Grey literature reports and dossiers that may 
be used in healthcare decision-making but were not 
published in the peer-reviewed literature and excluded 
from our study. Finally, a formal HTA agency for China 
was only established in October 2018. Previously the lack 
of a HTA agency in China to encourage the provision of 
economic evidence may have limited public and private 
funding for CEA research. Neumann et al found that the 
top countries publishing (English-language) cost-effec-
tiveness studies across all types of sponsorship were the 
USA, UK, Canada, the Netherlands and Sweden. The 
latter four countries have well-established HTA agencies 
which recommend cost-per-QALY analysis, and interest 
in these studies to support decision-making in the USA 
is growing.16
CEAs focused on China are mainly published by authors 
affiliated with Chinese institutions. This trend is expected 
to continue as the number and size of health economic 
research groups at Chinese universities continues to grow 
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and government policies encourage comparative effec-
tiveness research.17
The QALY continues to establish itself as the preferred 
unit of health benefit for CEA in China among published 
CEAs and there has been rapid growth in cost-per-QALY 
studies in recent years. The first three cost-per-QALY 
studies were published in 2008, we do not believe this was 
associated with any particular local political or method-
ological development. More recently, the EQ-5D value set 
for China was published in 2017, which enables QALYs 
to be estimated that reflect the preferences of the local 
Chinese population, removing an important limitation of 
earlier cost-per-QALY studies conducted in China.18 As 
infectious diseases still pose substantial disease burden 
in China and many of China-based cost-per-DALY studies 
focused on these areas, cost-per-DALY studies could 
also provide important information for priority settings 
among public health interventions in China.
The pharmaceutical industry is a relatively minor 
sponsor of cost-per-QALY studies in China when 
compared with international trends (14% in China vs 
24% internationally reported by Neumann et al5). These 
differences may reflect the lack of explicit guidance or 
mandate from the Chinese government that companies 
should provide cost-per-QALY evidence for pricing and 
reimbursement decision-making.
Our finding that ICERs relating to oncology studies 
were likely to be higher than the median ICER was 
similar to other studies and highlights that there may 
be systematic differences between cost-effectiveness 
estimates across disease areas.19 Given that there is no 
agreed cost-effectiveness threshold for decision-making 
in China, these differences may have important implica-
tions for resource allocation.
There appeared to be no influence of industry on the 
level of the reported ICER of cost-per-QALY studies in 
contrast to a previous publication using the entire CEA 
Registry, which found that industry-sponsored studies 
were likely to have ICERs lower than the median.20 That 
said, the sample of industry-authored and industry-spon-
sored studies is currently small in China, so it would be 
interesting to replicate the analysis in the future with a 
larger sample.
Our finding that CEA studies in China are of a generally 
high quality is in line with previous publications. Jiang et 
al found that China-based English-language studies had 
an average Quality of Health Economic Studies scale 
score of 80 out of 100, and we found that cost-per-QALY 
studies were of higher quality than previous studies 
using the CEA Registry and cost-per-DALY studies were 
of comparable quality to previous studies using the GH 
CEA Registry.5 11 15 Of the 20 studies identified by Jiang et 
al, 11 were also in our review and had a mean score of 4.9 
in the CEA Registry quality rating. The nine studies not 
included in our review were due to Chinese language (2) 
non-QALY/DALY unit of benefit (2) not mainland China 
(3) and no mention of QALY/DALY in title or abstract 
(1).
This study has several limitations. The CEA Registry 
focuses on two particular forms of CEA, often called 
cost-utility analysis (CUA): cost-per-QALY gained and 
cost-per-DALY averted studies. Other forms of economic 
evaluation that employ other benefit measures, such as 
disease-specific outcome measures or cost-benefit anal-
ysis, are not included in this study. The restriction on 
CUAs allows more robust methodological and quality 
comparisons across the included studies.
Second, the CEA Registry indexes English-language 
literature and therefore publications in local language 
peer-reviewed journals were not included in this review. 
While the inclusion of Chinese-language publications 
might be expected to increase the number of articles 
identified, the use of the CEA Registry provides a rigorous 
and standardised methodology identifying and classi-
fying CEA literature, facilitating comparisons between 
international studies.
Furthermore, the number of studies identified in this 
review compares favourably with previously published 
systematic reviews of the Chinese CEA literature.11 12 21 
The most recently published review by Ma et al, which 
focused on study quality, included 32 pharmacoeconomic 
studies published up to 2014.12 Their review covered 
additional regions (studies relating to Special Adminis-
trative Regions, such as Hong Kong, were included) and 
also covered measures of effectiveness aside from the 
QALY or DALY. Over the same time period, our review 
included 78 cost-per-DALY or cost-per-QALY studies for 
mainland China.
In light of the increasing importance of CEA in 
China, we make a number of recommendations for 
policymakers dealing with the limited evidence base. A 
challenge in the interpretation of CEAs in China is the 
absence of an agreed-upon national ICER benchmark 
or threshold. This is in part due to regional inequality, 
which means that any standard (eg, one-time GDP per 
capita) would have different implications for different 
parts of China, where drug budgets are devolved to 
local provinces.22 We found that most studies were 
using national GDP per capita to determine a cost-ef-
fectiveness threshold.
Although GDP per capita-based thresholds were 
originally recommended by the WHO, they were not 
empirically derived.23 Many researches have argued that 
thresholds should reflect the opportunity cost of health, 
which has not been estimated for China to date.24 Deci-
sions based on a GDP-per-capita threshold may lead to 
inappropriate recommendations as well as misallocation 
of resources,25 and further research into appropriate 
thresholds for China would be valuable.
Evidence gaps have been noted in the CEA literature, 
with studies covering pharmaceutical interventions for 
conditions such as oncology and HIV relatively over-rep-
resented, whereas health education interventions and 
conditions such as injuries and substance abuse are rela-
tively under-represented.26 The disease areas we identi-
fied as the most common focus of CEA studies in China 
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(oncology, infectious and parasitic diseases, and endo-
crine, nutritional and metabolic diseases) had some simi-
larities with the leading causes of morbidity and mortality 
in China, suggesting that the cost-effectiveness literature 
for China is focused on areas relevant to policymakers. 
The Global Burden of Disease Study identified cerebro-
vascular disease as the leading cause of years of life lost 
(YLL) in 2013, whereas diseases of the circulatory system 
was the topic of only 9% of cost-per-QALY studies and 4% 
of cost-per-DALY studies in China.27 Cancer, the leading 
topic of cost-per-QALY studies and third most common 
topic of cost-per-DALY studies, has been a growing cause 
of YLL in the Global Burden of Disease Study and is the 
leading cause of death in China’s national statistics.27 28 A 
more detailed analysis of evidence gaps in China may be 
valuable to guide limited financial and human resources 
to conduct the most valuable economic evaluations.
While policymaker’s desire to incorporate economic 
evidence into coverage decision has been growing in 
China, there is a need to apply economic evidence 
generated elsewhere to local settings due to the lack of 
available evidence specific to China. Further efforts to 
evaluate transferability of findings would be necessary 
based on potential differences in population characteris-
tics, disease epidemiology, relative prices, health systems 
and other factors. The development of an explicit refer-
ence-case CEA is also highly recommended to help 
comparisons across studies, as the conclusions of studies 
are sensitive to the features of the local healthcare system 
and societal preferences.
A Chinese-language CEA Registry would be helpful for 
policymakers to keep track of the Chinese CEA literature 
in a similar way to the international literature. Over the 
longer term, policies to encourage open publication of 
CEA studies in the peer-reviewed literature and develop-
ment of domestic research capacity to undertake studies 
will help fill the evidence gaps.
ConClusIon
The body of CEA literature relating to China has 
grown rapidly in recent years, though the number of 
published studies remains a small proportion of studies 
published globally. In light of the growing importance 
of CEA to policymakers, there is a need to critically 
interpret evidence from different geographies and 
settings by adapting models or input parameters to 
the China situation. Policies to encourage the peer-re-
viewed publication of analysis and to support capacity 
building in domestic health economic research are 
recommended.
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